Article in Toxins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Benjamin WaeschleInstitute of Pharmaceutical and Medicinal Chemistry, Faculty of Mathematics and Natural Sciences, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
John-Ih LeeDepartment of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.ORCID 0000-0001-9622-0216
Tristan KölscheDepartment of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.ORCID 0009-0002-4075-669X
Robin JansenDepartment of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.ORCID 0009-0005-8492-7595
Marta BanachDepartment of Neurology, Collegium Medicum, Jagiellonian University, 31-008 Kraków, Poland.
Stanislaw OchudloMedical Practice Dr. Stanislaw Ochudlo, 40-097 Katowice, Poland.
Małgorzata TyślerowiczDepartment of Neurology, Copernicus Memorial Hospital in Lodz, Comprehensive Cancer Centre and Traumatology, 93-513 Lodz, Poland.
Piotr SobolewskiDepartment of Neurology and Stroke Unit in Sandomierz, Jan Kochanowski University, 25-369 Kielce, Poland.ORCID 0000-0003-4646-1702
Eva López-ValdésHospital Clínico San Carlos, 28040 Madrid, Spain.
Pablo MirUnidad de Trastornos del Movimiento, Servicio de Neurología, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Seville, Spain.ORCID 0000-0003-1656-302X
Silvia JesúsUnidad de Trastornos del Movimiento, Servicio de Neurología, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Seville, Spain.
Elena Ojeda-LepeUnidad de Trastornos del Movimiento, Servicio de Neurología, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Seville, Spain.
Ewa PapućDepartment of Neurology, Medical University of Lublin, 20-093 Lubin, Poland.
Pilar Sánchez AlonsoMovement Disorders Unit, Department of Neurology, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, Spain.ORCID 0000-0003-0496-4707
Gabriel SalazarDepartment of Neurology, Hospital Universitario de Terrassa CST, 08221 Terrassa, Spain.ORCID 0000-0002-7958-6862
Holger StarkInstitute of Pharmaceutical and Medicinal Chemistry, Faculty of Mathematics and Natural Sciences, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.ORCID 0000-0003-3336-1710
Philipp AlbrechtDepartment of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.ORCID 0000-0001-7987-658X
Funding
Merz Therapeutics GmbH NA
6 · The paper itself
Abstract
The RELY-CD study investigated the long-term clinical response to botulinum neurotoxin type A in cervical dystonia within a multicenter, real-world setting. This retrospective study focused on patients treated with complex-free (incobotulinumtoxinA) and complex-containing (onabotulinumtoxinA and abobotulinumtoxinA) BoNT/A formulations over an up to 10-year period. The novel dose-effect parameter "DEff" was introduced to quantify the relationship between dose adjustments and clinical outcomes, enabling the identification of partial treatment failures. The primary endpoint was a comparison of a clinically meaningful worsening in DEff in treatment year 7 compared to year 2 between complex-free and complex-containing botulinum neurotoxin type A. The RELY-CD study provides unique insights into long-term treatment patterns, clinical resistance phenomena, and the implications of formulation differences on treatment outcomes, addressing a critical gap in the literature on real-world botulinum neurotoxin type A application. The study methodology, including the definition and calculation of the novel DEff, as well as clinical baseline characteristics, are presented.
Indexed as
Botulinum Toxins, Type ANeuromuscular AgentsTorticollisAdultAgedFemaleHumansMaleMiddle AgedMulticenter Studies as TopicObservational Studies as TopicRetrospective StudiesTreatment OutcomeabobotulinumtoxinABotulinum Toxins, Type AincobotulinumtoxinANeuromuscular AgentsabobotulinumtoxinAbotulinum toxincervical dystoniaimmunogenicityincobotulinumtoxinAlong-term treatmentonabotulinumtoxinAreal-world evidence
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Protocol and Demographics of the RELY-CD Study: Assessing Long-Term Clinical Response to Botulinum Neurotoxin in Cervical Dystonia. · full record | OpenQuestion